<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="195969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540059</url>
  </required_header>
  <id_info>
    <org_study_id>Zx-002</org_study_id>
    <nct_id>NCT00540059</nct_id>
  </id_info>
  <brief_title>Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial</brief_title>
  <official_title>Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8
      SafeSystem for advanced PCa under naturalistic conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">1950</enrollment>
  <condition>Prostate Carcinoma</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with PCa, who will be treated with Zoladex 10,8 SafeSystem based on the
             current SPC
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H Brasch</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>August 2007</verification_date>
  <lastchanged_date>October 4, 2007</lastchanged_date>
  <firstreceived_date>October 3, 2007</firstreceived_date>
  <keyword>Prostate carcinoma</keyword>
  <keyword>LHRH</keyword>
  <keyword>Zoladex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
